Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.39 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28030489 | 0.96 | CYP1A2 (0.47) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL6089429 | 0.82 | CCNB2 (0.34) | CCNB2CCNE2CDK1CCNB1CCNE1 | |
| SCHEMBL5584092 | 0.79 | GPR84 (0.49) | CYP1A2CYP2C9CYP2C19CDK1CDK2 | |
| SCHEMBL7741609 | 0.78 | LIPG (0.46) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL8858058 | 0.78 | CYP1A2 (0.45) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL7207311 | 0.78 | LIPG (0.46) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL5138400 | 0.78 | LIPG (0.46) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL4475658 | 0.78 | LIPG (0.46) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL2410544 | 0.78 | LIPG (0.46) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL27742366 | 0.78 | LIPG (0.46) | CYP1A2CYP2D6CYP19A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019005-B2 | 3 (5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors | G. D. SEARLE & CO. (US) | 2006-03-28 | — | — | US | disclosed |
| US-20040147579-A1 | 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors | PHARMACIA CORPORATION | 2004-07-29 | — | — | US | disclosed |
| US-6579873-B2 | Treatment of inflammation, arthritis, bone disorders, respiratory system disorders | PHARMACIA CORPORATION | 2003-06-17 | — | — | US | disclosed |
| US-20020086869-A1 | 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors | PHARMACIA CORPORATION | 2002-07-04 | — | — | US | disclosed |
| US-6335336-B1 | TREATING TUMOR NECROSIS FACTOR AND MITOGEN-ACTIVATED PROTEIN KINASE(MAP) MEDIATED DISORDERS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS; INFLAMMATORY BOWEL DISEASE | G.D. SEARLE & COMPANY | 2002-01-01 | — | — | US | disclosed |
| US-6087496-A | ENZYME INHIBITORS | G. D. SEARLE & CO. (US) | 2000-07-11 | — | — | US | disclosed |
| EP-0983260-A2 | 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS | G.D. Searle & Co. (US) | 2000-03-08 | — | — | EP | disclosed |
| US-5932576-A | USEFUL FOR TREATING P38 KINASE MEDIATED DISORDERS SUCH AS ATHEROSCLEROSIS, RHEUMATIOD ARTHRITIS, INFLAMMATORY BOWEL DISEASE, PSORIASIS AND OTHERS | G. D. SEARLE & COMPANY (US) | 1999-08-03 | — | — | US | disclosed |
| WO-1998052937-A2 | 4-ARYL-3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS P38 KINASE | G.D. SEARLE AND CO. (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147579-A1 | 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors | MAPK1, MAPKAPK2, MAPK3 | CYP1A2 238/4885CYP2D6 949/4885CYP19A1 917/4885 |
| US-20020086869-A1 | 3 (5) -heteroaryl substituted pyrazoles as p38 kinase inhibitors | MAPK1, MAPKAPK2, MAPK3 | CYP1A2 238/4885CYP2D6 949/4885CYP19A1 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.